Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines

被引:76
作者
Gu, YP
Li, HZ
Miki, J
Kim, KH
Furusato, B
Sesterhenn, IA
Chu, WS
McLeod, DG
Srivastava, S
Ewing, CM
Isaacs, WB
Rhim, JS
机构
[1] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Bethesda, MD 20814 USA
[2] Armed Forces Inst Pathol, Washington, DC 20307 USA
[3] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[4] Johns Hopkins Med Inst, Baltimore, MD 21287 USA
关键词
telomerase; immortalization; primary prostate tumor cell lines; primary non-malignant prostate cell lines;
D O I
10.1016/j.yexcr.2005.11.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In vitro human prostate cell culture models are critical for clarifying the mechanism of prostate cancer progression and for testing preventive and therapeutic agents. Cell lines ideal for the study of human primary prostate tumors would be those derived from spontaneously immortalized tumor cells; unfortunately, explanted primary prostate cells survive only short-term in culture, and rarely immortalize spontaneously. Therefore, we recently have generated five immortal human prostate epithelial cell cultures derived from both the benign and malignant tissues of prostate cancer patients with telomerase, a gene that prevents cellular senescence. Examination of these cell lines for their morphologies and proliferative capacities, their abilities to grow in low serum, to respond to androgen stimulation, to grow above the agar layer, to form tumors in SCID mice, suggests that they may serve as valid, useful tools for the elucidation of early events in prostate tumorigenesis. Furthermore, the chromosome alterations observed in these immortalized cell lines expressing aspects of the malignant phenotypes imply that these cell lines accurately recapitulate the genetic composition of primary tumors. These novel in vitro models may offer unique models for the study of prostate carcinogenesis and also provide the means for testing both chemopreventive and chemotherapeutic agents.
引用
收藏
页码:831 / 843
页数:13
相关论文
共 51 条
[1]   Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43 [J].
Berthon, P ;
Valeri, A ;
Cohen-Akenine, A ;
Drelon, E ;
Paiss, T ;
Wöhr, G ;
Latil, A ;
Millasseau, P ;
Mellah, I ;
Cohen, N ;
Blanché, H ;
Bellané-Chantelot, C ;
Demenais, F ;
Teillac, P ;
Le Duc, A ;
de Petriconi, R ;
Hautmann, R ;
Chumakov, I ;
Bachner, L ;
Maitland, NJ ;
Lidereau, R ;
Vogel, W ;
Fournier, G ;
Mangin, P ;
Cohen, D ;
Cussenot, O .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (06) :1416-1424
[2]  
Bonkhoff H, 1996, PROSTATE, V28, P98
[3]  
Bright RK, 1997, CANCER RES, V57, P995
[4]  
Brothman AR, 1999, PROSTATE, V38, P303
[5]  
Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO
[6]  
2-1
[7]  
Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO
[8]  
2-G
[9]  
DELAUNOIT Y, 1991, CANCER RES, V51, P5165
[10]  
Ellis WJ, 1996, CLIN CANCER RES, V2, P1039